CV Science

André Pèlegrin PhD, Biomedical Engineering, Therapeutic Antibodies

Course and current status

• March 2011 to the present Deputy Coordinator LabEx MAbImprove (http://mabimprove.univ-tours.fr)

• Jan. 2008 — Dec. 2014       Director IRCM, Institut de Recherche en Cancérologie de Montpellier

• Jan. 2007 — Dec. 2007       Director U860 " Immunotargeting and Radiobiology in Oncology"

• 2002 — Dec. 2006              Director EMI0227 "Tumor Immunotargeting and Antibodies Ingeneering"

• 1997 — 2001                     Group Leader, JE2176 then EA2989 "Experimental Oncology and Tumor

                                        Immunotargeting", University of Montpellier I

• Sept., 1994—Nov., 2000      Research Engineer, Faculty of Medicine, University of Montpellier I

• Oct., 1992—Aug., 1994       Investigator, Nuclear Medicine Department, Val d’Aurelle Cancer Center

• Jan., 1988—Sept., 1992      Research Assistant, Biochemistry Institute, University of Lausanne, Suisse

• Dec., 1984—Dec., 1987      PhD student, Faculty of Pharmacy, University of Montpellier I

• Dec., 1983—Nov., 1984      Assistant, Faculty of Dental Medicine, Rabat, Maroc

• 1996       Accreditation to supervise research in Oncology (HDR), Montpellier University

• 1988       PhD in Immunology, Montpellier University

• 1985       Graduate course in Immunology and Immunotechnology, Montpellier University

• 1982       Master of Science Degree (DEA) in Therapeutic Chemistry, Montpellier University

• 1981       Bachelor of Science Degree in Biochemistry, Marseille University

Scientific summary

The research topics, fields of expertise and main objectives of my research group “Immunotargeting and Radiobiology in Oncology” at IRCM are:

• Research topics: treatment of solid tumors by using antibodies and radiotherapy with a special attention to drug-induced resistance
• Fields of expertise: Antibodies engineering, Radiobiology, Evaluation of the different therapeutic approaches using both in vitro systems, animal models and clinical trials
• Main objectives: To design, develop and evaluate monoclonal antibodies (mAbs) to target antigens the expression of which is enhanced when tumors become resistant to a treatment and to combine them to identify synthetic lethal interactions for anti-cancer drug discovery/improvement; To improve the efficacy of these targeted therapeutic approaches; To understand the underlying mechanisms of action

Our research is organized around 4 closely related research themes

• Human Epidermal Receptor (HER) family: from combinations of approved monoclonal antibodies (mAbs) to original mAbs against receptors and ligands, and back
• TfR1/CD71: where iron metabolism meets anti-Tyrosine kinase (TK) antibodies
• MISR-II: the original ovarian carcinoma target
• Severe late adverse effects after radiotherapy: analysis of the causes and design of a predictive assay